CV Sciences (CVSI) Capital Expenditures Growth (5y) (2018 - 2026)
CV Sciences (CVSI) Capital Expenditures Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.81 Bn | 32.07 Bn | 1.97 Bn |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.72 Bn | 16.40 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.56 Bn | 12.13 Bn | 785.00 Mn |
| 10 | CV Sciences | 4.11 Mn | 3.80 Mn | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.82% |
| Dec 31, 2025 | -59.42% |
| Sep 30, 2025 | 15.34% |
| Jun 30, 2025 | -35.23% |
| Mar 31, 2025 | -12.05% |
| Dec 31, 2024 | -56.27% |
| Dec 31, 2020 | 103.32% |
| Sep 30, 2020 | -1,117.03% |
| Jun 30, 2020 | 94.91% |
| Mar 31, 2020 | 0.35% |
| Dec 31, 2019 | 61.83% |
| Sep 30, 2019 | -17.26% |
| Jun 30, 2019 | -24.56% |
| Dec 31, 2018 | 103.81% |
| Jun 30, 2018 | -58.82% |